Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (492)	10/15/1998 3:13:00 PM
From: Gerald Underwood	Read Replies (1) \| Respond to of 857

Marty, My take is EXCLUSIVE for seven years after approval by FDA. Yes it could be huge. Hep B and C could be even larger however not without some competition. I am unaware if HEB is taking advantage of all of these incentives, but would surmise that Dr. Carter is certainly astute enough to utilize this advantage to the best interests of the stockholders. I think the part about the open protocols is possibly one of the most important factors in the incentives. Gerry